Windsor Capital Management LLC Takes Position in Astrazeneca Plc $AZN

Windsor Capital Management LLC purchased a new position in shares of Astrazeneca Plc (NYSE:AZN) in the second quarter, Holdings Channel.com reports. The fund purchased 3,539 shares of the company’s stock, valued at approximately $671,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in AZN. Triumph Capital Management acquired a new position in Astrazeneca in the third quarter valued at approximately $25,000. MV Capital Management Inc. purchased a new position in Astrazeneca in the fourth quarter worth approximately $26,000. Mascoma Wealth Management LLC acquired a new stake in Astrazeneca during the first quarter worth $26,000. Roxbury Financial LLC acquired a new stake in Astrazeneca during the second quarter worth $29,000. Finally, Eagle Bay Advisors LLC acquired a new stake in Astrazeneca during the fourth quarter worth $30,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on AZN shares. Bank of America reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Wednesday, July 1st. Wall Street Zen downgraded Astrazeneca from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Jefferies Financial Group restated a “buy” rating on shares of Astrazeneca in a report on Friday, June 26th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Tuesday, June 30th. Finally, DZ Bank raised shares of Astrazeneca from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 29th. Twelve investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Astrazeneca currently has an average rating of “Moderate Buy” and an average price target of $211.00.

Astrazeneca Stock Up 0.1%

Shares of NYSE AZN opened at $161.28 on Friday. The company has a quick ratio of 0.67, a current ratio of 0.89 and a debt-to-equity ratio of 0.47. The business’s 50 day moving average is $176.34 and its two-hundred day moving average is $187.12. Astrazeneca Plc has a 52-week low of $145.79 and a 52-week high of $212.71. The firm has a market cap of $250.12 billion, a price-to-earnings ratio of 24.11, a PEG ratio of 1.39 and a beta of 0.26.

Astrazeneca (NYSE:AZN) last released its quarterly earnings results on Monday, July 27th. The company reported $2.63 EPS for the quarter, topping the consensus estimate of $2.50 by $0.13. Astrazeneca had a return on equity of 31.45% and a net margin of 17.02%.The business had revenue of $15.38 billion during the quarter, compared to analyst estimates of $15.44 billion. During the same period last year, the business posted $2.17 earnings per share. The company’s quarterly revenue was up 6.4% on a year-over-year basis. Research analysts predict that Astrazeneca Plc will post 10.22 EPS for the current year.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.